Cart
sales@molnova.com
Sirpiglenastat
CAS No. 2079939-05-0
Sirpiglenastat( —— )
Catalog No. M35655 CAS No. 2079939-05-0
Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 871 | In Stock |
|
| 5MG | 896 | In Stock |
|
| 10MG | 1207 | In Stock |
|
| 25MG | 1786 | In Stock |
|
| 50MG | 2353 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSirpiglenastat
-
NoteResearch use only, not for human use.
-
Brief DescriptionSirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.
-
DescriptionSirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
-
In VitroSirpiglenastat (DRP-104) treatment shows broad immune cell modulation effects including increased T, NK, and macrophages. Sirpiglenastat decreases pro-tumorigenic cytokines such as VEGF and KC (IL-8).
-
In VivoCT26 bearing mice treated with Sirpiglenastat (DRP-104) (0.5 mg/kg; s.c.; once a day; for 5 days) shows tumor growth inhibition at day 12 of 90%. Median survival days are 36 days. Sirpiglenastat (0.5 mg/kg; s.c) treatment significantly inhibits tumor growth in the H22 model.Animal Model:CT26 bearing mice Dosage:0.5 mg/kg Administration:s.c.; once a day; for 5 days Result:Showed tumor growth inhibition in mice.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorGlutaminase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2079939-05-0
-
Formula Weight441.48
-
Molecular FormulaC22H27N5O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (226.51 mM; Ultrasonic )
-
SMILESC([C@@H](C(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)NC(C)=O)C=1C=2C(NC1)=CC=CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yumi Yokoyama, et al. DRP-104, a novel broad acting glutamine antagonist, induces distinctive immune modulation mechanisms and synergistic efficacy in combination with immune checkpoint blockade. J Immunother Cancer. 2019 Nov 6;7(Suppl 1):282.?
molnova catalog
related products
-
Potassium antimonyl ...
Antimony potassium tartrate also known as potassium antimonyl tartrate potassium antimontarterate or emetic tartar has the formula K2Sb2(C4H2O6)2 and is the double salt of potassium and antimony of tartaric acid.
-
5'-O-(4,4'-Dimethoxy...
5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine is a competitive dUTP nucleotidohydrolase (dUTPase) inhibitor(Ki > 1 mM) in E. coli.
-
Albanin A
Albanin A, a flavonoid, suppresses glutamate release by decreasing Ca2+/calmodulin/adenylate Cyclase 1 (AC1) activation in synaptosomes and exerts neuroprotective effect in vivo. Albanin A has anti-inflflammatory activity.
